Fresenius Kabi Announces U.S. Availability of Omegaven® (fish oil triglycerides) Injectable Emulsion

In a recent press release, Fresenius Kabi has announced the release of the first and only FDA-approved lipid emultion to address nutritional needs of pediatric patients suffering from life-threatening conditions.
 

Advertisement

 

 

Editor’s Note: This article originally appeared on Fresenius Kabi’s website.

Fresenius Kabi, a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition, announced today that Omegaven® (fish oil triglycerides) injectable emulsion is now commercially available in the United States. This novel lipid had previously been available only for compassionate use in the U.S.

Omegaven is an intravenous lipid emulsion that provides calories and fatty acids for pediatric patients with parenteral nutrition-associated cholestasis, or PNAC. Omegaven is the first and only FDA-approved fish oil lipid emulsion for this condition. Click here to continue>>

 

News from our partners.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Care Coordination

Advertisement

Comments are closed.